Results 51 to 60 of about 9,286 (149)

Pediatric Systemic Lupus Erythematosus Complicated by Acute EBV and CMV Co‐infection

Journal of Clinical Laboratory Analysis, Volume 40, Issue 17, September 2026.
This case report describes a 10‐year‐old girl with new‐onset pediatric SLE who presented with malar rash, fever, and arthritis following sun exposure, alongside serological evidence of acute Epstein–Barr virus (EBV) and cytomegalovirus (CMV) co‐infection.
Anning Chen, Gengchun Ji, Ziping Lan, Ping Li, Jianwei Wang, Le Zhang, Chaojun Hu, Shulan Zhang   +7 more
wiley   +1 more source

Effects of oral valganciclovir prophylaxis for cytomegalovirus infection in heart transplant patients

Drug Design, Development and Therapy, 2012
Andreas O Doesch,1 Janika Repp,1 Nina Hofmann,1 Christian Erbel,1 Lutz Frankenstein,1 Christian A Gleissner,1 Constanze Schmidt,1 Arjang Ruhparwar,2 Christian Zugck,1 Paul Schnitzler,3 Philipp Ehlermann,1 Thomas J Dengler,4 Hugo A Katus11Department of ...
Doesch AO, Repp J, Hofmann N, Erbel C, Frankenstein L, Gleissner CA, Schmidt C, Ruhparwar A, Zugck C, Schnitzler P, Ehlermann P, Dengler TJ, Katus HA   +12 more
doaj  

Efficacy of Low Dose Valganciclovir Prophylaxis for Cytomegalovirus Infection in Kidney Transplantation

Haseki Tıp Bülteni, 2020
Aim:Valganciclovir is the preferred drug for chemoprophylaxis for the prevention of cytomegalovirus (CMV) infection in kidney recipients. Low-dose (450 mg/day) valganciclovir use is gaining popularity because standard dose (900 mg/day) has negative ...
Ümit Özçelik, Nadir Alpay, Eryiğit Eren, Bora Uslu, Ahmet Cem Yardımcı   +4 more
doaj   +1 more source

Effectiveness of Valganciclovir 900mg Versus 450mg for Cytomegalovirus Prophylaxis in Renal Transplantation: A Systematic Review and Meta-Analysis

Journal of Pharmacy & Pharmaceutical Sciences, 2017
Objectives: Valganciclovir 900 mg/day is approved for cytomegalovirus (CMV) prophylaxis, but 450 mg/day is seems also effective. We systematically reviewed the efficacy and safety of low-dose versus high-dose valganciclovir prophylaxis in renal ...
wang xin, yang hui, zhang xiaodong, cui xiangli, wang shihui, liu lihong   +5 more
doaj   +1 more source

High burden of CMV infections after simultaneous pancreas-kidney transplantation—a nationwide cohort study

Frontiers in Transplantation
Cytomegalovirus (CMV) infections remain a common problem after solid-organ transplantation. We characterized the burden of CMV infections, and adverse events of CMV prophylaxis after simultaneous pancreas-kidney transplantation (SPK). We included all SPK
Kaisa Ahopelto, Juulia Grasberger, Fernanda Ortiz, Agneta Ekstrand, Arno Nordin, Marko Lempinen, Ilkka Helanterä   +6 more
doaj   +1 more source

Valganciclovir in the treatment of cytomegalovirus retinitis in HIV-infected patients

Clinical Ophthalmology, 2010
A Jayaprakash Patil1,2,3, Ashish Sharma1,4, M Cristina Kenney1, Baruch D Kuppermann11Department of Ophthalmology, Gavin S Herbert Eye Institute, University of California, Irvine, Irvine, CA, USA; 2Department of Ophthalmology, Summa Health System, Akron ...
A Jayaprakash Patil, Ashish Sharma, M Cristina Kenney, et al   +3 more
doaj  

Pre-Transplant Frequencies of FoxP3+CD25+ in CD3+CD8+ T Cells as Potential Predictors for CMV in CMV-Intermediate Risk Kidney Transplant Recipients

Transplant International
Cytomegalovirus (CMV) infection detrimentally influences graft survival in kidney transplant recipients, with the risk primarily determined by recipient and donor serostatus. However, recipient CD8+ T cells play a crucial role in CMV control. The optimal
Agnes A. Mooslechner, Agnes A. Mooslechner, Max Schuller, Verena Pfeifer, Verena Pfeifer, Konstantin A. Klötzer, Barbara Prietl, Barbara Prietl, Alexander H. Kirsch, Philipp Stiegler, Robert Sucher, Harald Sourij, Alexander R. Rosenkranz, Kathrin Eller   +13 more
doaj   +1 more source

Role of oral valganciclovir in sick preterm with cytomegalovirus virus infection and ventilation dependence

Indian Journal of Respiratory Care, 2019
Cytomegalovirus (CMV) is the most common congenital viral infection in neonates. Postnatal infection regarding infants rarely has significant clinical consequences. However, preterm may be at higher risk of developing symptomatic postnatal CMV disease. A
Anumodan Gupta, Aditi Saini, Anukul Gowda, Sandeep Kadam   +3 more
doaj   +1 more source

Does Cytomegalovirus Develop Resistance following Antiviral Prophylaxis and Treatment in Renal Transplant Patients in Kuwait?

Advances in Virology, 2011
The resistance of cytomegalovirus (CMV) to ganciclovir or valganciclovir is a factor in therapeutic failure and disease progression. CMV strains resistant to ganciclovir or valganciclovir have been associated with specific mutations in the UL97 and UL54 ...
Nada Madi, Widad Al-Nakib, Alexander Pacsa   +2 more
doaj   +1 more source

Pitfalls in Valganciclovir Prophylaxis Dose Adjustment Based on Renal Function in Kidney Transplant Recipients

Transplant International
Valganciclovir (VGC) is administered as prophylaxis to kidney transplant recipients (KTR) CMV donor (D)+/recipient (R)− and CMV R+ after thymoglobulin-induction (R+/TG).
Nathalie Hammer, Linard Hoessly, Fadi Haidar, Cédric Hirzel, Sophie de Seigneux, Christian van Delden, Bruno Vogt, Daniel Sidler, Dionysios Neofytos   +8 more
doaj   +1 more source